

# a biotechne brand Autophagy Handbook



 $\bigcirc$ 

The term "Autophagy" is derived from the Greek word αύτόφαγος autóphagos that means "self-devouring"

### **TABLE OF CONTENTS**

1	Introduction	
2	<b>Types of Autophagy</b> Macroautophagy, Microautophagy and Chaperone-Mediated Autophagy	
3-4	Selective Autophagy Types of Selective Autophagy Receptors LC3 Isoforms	
5-6	Autophagic Machinery and Flux Proteins Playing Key Roles in Autophagy	
7-14	Measuring Autophagy Steady-State Assay: Autophagosome Number Protocol: Detection of Autophagosome Number by LC3 Immunocytochemistry (ICC/IF) Monitoring Autophagic Flux Protocol: LC3-II Turnover Assay by Western Blot	
14-16	Alternate Targets to Study Autophagy p62/SQSTM1-Structural Domains Relevant in Autophagy Considerations for p62/SQSTM1 Quantitation Additional Recommended Targets to Monitor Autophagy Additional Methods to Monitor Autophagy	
17	Simple Western for Autophagy Targets Bio-techne: Select Autophagy Antibodies Validated for Simple Western	
18-19	Modulators of Autophagy Small Molecule Modulators Specific Induction of Autophagy: Tat Beclin Peptides	
20-21	Nuclear Control of Autophagy Transcriptional Mechanisms Regulating Autophagy Epigenetic Control of Autophagy	
22	Advanced Cell Diagnostics (ACD) RNAscope® Signal Amplification is Achieved by a Cascade of Hybridization Events	
23-24	Select References, Acronyms and Abbreviations	

# Introduction

Autophagy is a conserved cellular process for the delivery of macromolecules and organelles into lysosomes for degradation and recycling. This process targets excess and defective organelles as well as aggregated and long-lived proteins for elimination. Following hydrolysis, basic molecular components are recycled into the cytosol to serve as building blocks or as energy resources. Therefore, autophagy plays a critical role as a cellular homeostatic mechanism, controlling the balance between available resources and energy expenditure. Several cellular stressors including nutrient deprivation, hypoxia and ER stress may induce autophagy above basal levels. Additionally, deregulated autophagy is implicated in disease states including neurodegeneration and cancer.

### **Cytosolic Processing**



Figure 1. Autophagy depends on the formation of a double membrane organelle or autophagosome. Following induction, the initial membrane structure or phagophore elongates, engulfs cytosolic content and closes onto itself, forming the mature autophagosome. The fusion between the autophagosome and lysosome gives rise to the autophagolysosome where degradation of cytosolic material takes place.

This guide provides an overview of the process of autophagy. The main molecular players and regulatory pathways involved in the autophagic process are discussed. An emphasis on validated and standard methods for the quantification of autophagic activity will provide researchers with essential tools for optimizing autophagy measurements in their specific systems.

# **Types of Autophagy**

Three main types of autophagy are recognized that include **macroautophagy**, **microautophagy** and **chaperone-mediated autophagy**. In all these processes, cytosolic components reach the lysosomes for degradation, however specific differences in delivery mechanisms distinguish these processes.



#### Autophagy Mechanisms

Figure 2. Autophagy may be classified under three main categories including macroautophagy, microautophagy and chaperone-mediated autophagy. The autophagosome participates in the degradation of cytosolic components only during macroautophagy.

- Macroautophagy: Cytosolic components are sequestered within a double membrane organelle or autophagosome. Fusion
  of autophagosomes with lysosomes forms the autolysosome, where degradation of cytosolic components occurs. This guide
  focuses primarily on the process of macroautophagy (hereafter referred to as autophagy).
- Microautophagy: Lysosomes directly engulf cytosolic components via lysosomal membrane invagination.
- Chaperone-Mediated Autophagy: Chaperone proteins (e.g., heat shock cognate 70 protein; HSC-70) interact with cytosolic proteins destined for degradation. This complex is recognized by a lysosomal-associated membrane protein-2A (LAMP-2A), resulting in the translocation of the unfolded cytosolic protein into the lysosome.

# **Selective Autophagy**

Cytosolic components are targeted for degradation in bulk or by selective autophagy. Selective autophagy in mammals depends on two main components: selective-autophagy receptors and lipidated LC3 (microtubule-associated protein light chain 3) proteins. Their interaction ensures specific degradation of various cellular components including mitochondria, endoplasmic reticulum, aggregated proteins and ribosomes, among other components.

#### **Types of Selective Autophagy Receptors**

Selective autophagy pathways are broadly classified as ubiquitin-independent or -dependent and involve an adaptor protein or selective autophagy receptor that interacts directly or via ubiquitin with cellular targets, respectively.

- **Ubiquitin-Dependent Autophagy:** Selective autophagy receptors interact with ubiquitinated cargo via their ubiquitin binding domain (UBD). This selective autophagy pathway cooperates with the ubiquitin-proteasome system for the elimination of protein aggregates. Many other cellular components are targeted for degradation by these receptors. The factors that determine the specificity of the receptor to cargo interactions have not been completely elucidated. Considerable overlap exists in the selectivity of the receptors.
- Ubiquitin-Independent Autophagy: Receptors target directly a variety of molecules and organelles as cargo including
  proteins, lipids, peroxisomes and lysosomes, among many other cellular components.



Figure 3. Selective autophagy receptors contain an LC3 interacting region (LIR motif) for binding to LC3 family members. They interact with cellular cargo via a second binding motif that is ubiquitin-dependent or -independent.

### **Selective Autophagy Receptors**

Cytosolic Cargo	Ubiquitin-Dependent	Ubiquitin-Independent
Mitochondria	OPTN, NDP52, TAX1BP1, p62	NIX, BNIP3, FUNDC1, ATG32
Protein Aggregates	p62, NBR1, OPTN TOLLIP, Cue5	OPTN
Peroxisomes	NBR1, p62	ATG30, ATG36
Bacteria	p62, OPTN, NDP52, TAX1BP1	Galectin-8/NDP52
RNA granules	NDP52, p62	
Proteasome	RPN10	
Endoplasmic Reticulum		FAM134B, ATG40
Viruses		TRIM5α, SMURF1, p62
Nuclear Envelope		ATG39
Mitophagy Ribophagy Mitochondria Ribosomes Virophagy Circle Viruses Endoplasmic reticulum ER-phagy Xenophagy	Pexophagy Deroxisomes Lipid droplets Nucleophagy Nucle	Figure 4. Autophagy may occur in bulk or via a selective mechanism. Selective autophagy pathways are named based on the type of cargo targeted for degradation.

### LC3 Isoforms

Multiple LC3 family members have been identified in mammals that belong to two main sub-families, LC3 and GABARAP. Different isoforms may play specific roles in selective autophagy.

### LC3 and GABARAP Family Members

Sub-Family	Isoforms
LC3	MAP1LC3A, MAP1LC3B, MAP1LC3B2, MAP1LC3C
GABARAP	GABARAP, GABARAPL1, GABARAPL2, GABARAPL3*

Isoforms share 29-94% sequence identity. \*Only subfamily member not involved in formation of autophagosomes.

### **Autophagic Machinery and Flux**

A total of 31 autophagy-related proteins (ATG) regulate this process in yeast, and many ATG proteins are conserved in mammals. Each ATG protein supports specific steps in the dynamic process of autophagy.



• **Induction:** Starvation or reduced nutrient availability is one of the most studied triggers in autophagy research. The induction of autophagy in response to starvation is often dependent on the inhibition of mTOR kinase (mammalian target of rapamycin), a key regulator of nutrient signaling. Upon mTOR inhibition, the concomitant decrease in the phosphorylation status of a protein complex including ULK1 (unc-51-like kinase 1), ATG13 and RB1CC1 (RB1-inducible coiled-coil 1), increases the activity of ULK1 and induces autophagy.

# **Autophagic Machinery and Flux**

- Nucleation and Phagophore Formation: The membrane that forms the nascent phagophore may originate from the Golgi, endoplasmic reticulum, mitochondria or endosomes. Formation of the initial engulfing organelle or phagophore depends on the release of Beclin1 and AMBRA1 (activating molecule in BECN1 regulated autophagy protein 1) from their inhibitor Bcl-2. Release from inhibition allows for the formation of the PtdIns3K (class III phosphatidylinositol 3-kinase) complex including ATG14, VPS15 and VPS34 (vacuolar sorting proteins). This complex gives rise to phosphatidylinositol-3-phosphate and promotes the recruitment of ATG proteins into the nascent membrane.
- Elongation, Autophagosome Formation: Vesicle elongation is facilitated by the activation of two ubiquitin-like conjugation complexes. In the first complex, ATG7 and ATG10 participate in the covalent binding of ATG12 to ATG5. Interaction of the ATG12/ATG5 covalently-bound complex with ATG16L1 (ATG16-like 1) may promote the second ubiquitin-like conjugation complex. In the second complex, ATG4, ATG7 and ATG3 participate in the processing of soluble LC3 to its lipid conjugated form LC3-II. LC3 is lipidated to phosphatidylethanolamine groups associated with the phagophore's membrane. Together, these two ubiquitin-like conjugation complexes participate in the formation of the autophagosome. By the end of the elongation stage, the phagophore's membrane has expanded and closed onto itself completing the sequestration of cytosolic content. All ATG proteins dissociate from the autophagosome and return to the cytosol. Lipidated LC3 is the only ATG protein known to remain associated with the autophagosome's membrane.
- **Fusion and Degradation:** During starvation, the SNARE protein STX17 (syntaxin 17) localizes to completed autophagosomes. Interaction of STX17 with SNAP29 and lysosomal VAMP8 allows fusion of the autophagosome with lysosomes to form the mature hydrolytic organelle. Upon fusion, proton pumps and hydrolases are added to the autophagosome for formation of the autolysosome, enabling cargo acidification and hydrolysis.

ATG Proteins	Role in Autophagy	
ULK1 complex	Decreased phosphorylation activates complex of ULK1, ULK2, ATG13, ATG101 and FIP200 Involved in induction	
Class III phosphatidylinositol 3-kinase (PtdIns3K)	Complex of VPS34, VPS15, AMBRA1, UVRAG, BIF1, ATG14 and Beclin 1 Displacement of Bcl-2 activates VPS34 complex Involved in nucleation	
ATG9	Transmembrane protein present only in the phagophore Involved in nucleation	
Beclin/ATG6	Interacts with Bcl-2 Interacts with GAPR-1, a negative regulator of autophagy	
ATG7 and ATG10	E1 and E2-like enzymes Involved in the conjugation of ATG12-ATG5	
ATG12-ATG5 complex	Necessary for phagophore elongation	
ATG4	Cysteine protease that cleaves LC3	
ATG3	E2-like enzyme participates with ATG7 in the conversion of LC3-I to its lipidated form LC3-II	
p62/SQSTM1	Cargo receptor that is preferentially degraded by autophagy	
LC3/ATG8	Only ATG protein associated to the autophagosome's membrane	

### **Proteins Playing Key Roles in Autophagy**

Autophagy is a multistep and dynamic process that presents specific challenges for its quantitative assessment. Traditionally, the process of autophagy has been studied using electron microscopy. The discovery and characterization of the ATG proteins facilitated the development of molecular tools and approaches to identify and quantitate autophagic activity. Ideally, a combination of approaches should be implemented including steady-state and flux measurements for the assessment of autophagic activity in different systems.

#### Steady-State Assay: Autophagosome Number

Assays to determine the amount or number of autophagosomes generally focus on the LC3 protein. LC3 may be found in the cytosolic and nuclear compartments. The lipidated form or LC3-II is the only protein known to associate with the autophagosome's inner membrane. LC3-II levels detected by immunofluorescence (ICC/IHC/IF) and immunoassay (WB) provide a good estimation of autophagosome number. With over 500 citations, our LC3B antibody (catalog# NB100-2220) is the most widely trusted and used antibody to monitor LC3 levels.

• LC3-II Puncta (ICC/IHC/IF): This method combines the use of antibodies to LC3 and fluorescence microscopy to quantify fluorescent puncta, which correlate with the number of autophagosomes. This assay reports the number of puncta per cell or number of cells with puncta. Nevertheless, in most cells some basal autophagic activity is present and therefore most will have puncta.

### PROTOCOL: Detection of Autophagosome Number by LC3 Immunocytochemistry (ICC/IF)

#### **Materials**

- > 1X PBS
- > 4% paraformaldehyde in 1X PBS (make fresh)
- > 1X PBS with 0.5% Triton X-100
- > LC3 primary antibody in 1% normal serum or BSA in 1X PBS (~5 µg/mL or ~1:200 for catalog#

NB100-2220; 1:5,000 for catalog# NB600-1384)

- > Fluorophore-conjugated anti-rabbit secondary antibody in 1% normal serum or BSA in 1X PBS
- > 1-5% normal serum or BSA in 1X PBS
- > DAPI or Hoechst (1-10 µg/mL)







Figure 6. Immunocytochemistry/Immunofluorescence: Confocal analysis of HeLa cells using LC3B antibody (catalog# NB600-1384, 1:5,000). An Alexa Fluor 488-conjugated Goat anti-rabbit IgG was used as secondary antibody (Green). Actin filaments were labeled with Alexa Fluor 568 Phalloidin (Red). DAPI was used to stain the cell nuclei (Blue).

• LC3-Conversion (WB): This method measures the conversion of LC3, from unlipidated LC3-I to the lipidated form LC3-II. An increased conversion ratio correlates with increased autophagosome number. Quantification should be based on the comparison of LC3-II levels to the levels of a housekeeping protein (e.g., actin). However, in some systems the levels of housekeeping proteins are affected by autophagy and LC3-I may be used for comparison.

Caveats to the use of LC3 for the Assessment of Autophagic Activity	ICC/IHC	WB
1. Tissues and cells differ in the magnitude of LC3 turnover.	$\checkmark$	$\checkmark$
2. LC3-II level alone is not enough evidence of autophagy.	$\checkmark$	$\checkmark$
3. LC3-II may associate with other membranous structures.	$\checkmark$	$\checkmark$
4. Some antibodies may not sufficiently bind to LC3-I.	$\checkmark$	$\checkmark$
5. LC3-I is more sensitive to degradation than LC3-II.		$\checkmark$
6. LC3 protein levels may be heterogeneous in a cell population or tissue.		$\checkmark$
7. Different LC3 family members may be involved in autophagy requiring the use of multiple antibodies.	$\checkmark$	$\checkmark$

#### **Monitoring Autophagic Flux**

Autophagic flux refers to the complete processing of cargo, from sequestration to its degradation and recycling of basic components back to the cytosol.

• LC3 Turnover Assay (WB, ICC/IF): This assay monitors the accumulation of autophagosomes to determine autophagic flux. Lysosomotropic agents and protease inhibitors are used to block autophagic flux and prevent LC3-II degradation. The difference in the amount of LC3-II in the presence and absence of these agents provides a measure of autophagic flux. This assay allows researchers to distinguish between true autophagy induction and blockade of autophagic flux.

	Reagents for Autophagy Tu	rnover Assay	Inhibitory Mechanism
cal	<u>Chloroquine</u> <u>Bafilomycin A1</u> Ammonium chloride <u>Azithromycin</u>		Inhibitors of Lysosome Acidification
nacologi	<u>E64d</u> Pepstatin A <u>1</u>		Protease Inhibitors
Pharn	Xanthohumol ML 240		Inhibitors of Autophagosome Maturation
	<u>Nocodazole</u> <u>Vinblastine</u>		Inhibitors of Lysosome-Autophagosome Fusion
Genetic	*LAMP2/CD107b RNAi		Inhibitors of Autolysosome Maturation
	LAMP2 CRISPR Knockout		Inhibitors of Autolysosome Maturation
Available at Tocris: www.tocris.com *Available at Novus Biologicals: www.novusbio.com			

### PROTOCOL: LC3-II Turnover Assay by Western Blot

#### **Materials**

- > Chloroquine diphosphate (CQ) (10 mM) in dH<sub>2</sub>O
- > 1X PBS
- > Sample buffer, 2X Laemmli buffer: 4% SDS, 5% 2-mercaptoethanol (BME), 20% glycerol, 0.004% bromophenol blue, 0.125 M Tris-HCl, pH 6.8
- > RIPA buffer: 150 mM NaCl, 1% NP-40 or Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 8.0, 20 mM Tris-HCl, pH 7.5
- > 1X Running Buffer: 25 mM Tris-base, 192 mM glycine, 0.1% SDS. Adjust to pH 8.3
- > 1X Transfer buffer (wet): 25 mM Tris-base, 192 mM glycine, 20% methanol pH 8.3
- > TBS
- > TBST, TBS and 0.1% Tween
- > Blocking solution: TBST, 5% non-fat dry milk
- > Rabbit anti-LC3 primary antibody (catalog# NB100-2220) in blocking buffer (~2 µg/mL)







Figure 7. HeLa human cervical epithelial carcinoma parental cell line and LC3B knockout HeLa cell line (KO) were untreated (-) or treated (+) with 50  $\mu$ M Chloroquine for 18 hours. Whole cell protein lysates were prepared in 1x Laemmli sample buffer and approximately 10 µg of each lysate was separated on a 4-15% gel by SDS-PAGE, transferred to 0.2 µm PVDF membrane and blocked in 5% non-fat milk in TBST. PVDF membranes were probed with (A) rabbit anti-LC3B polyclonal (catalog# NB100-2220) and (B) rabbit anti-LC3B monoclonal (catalog# NBP2-46892) followed by HRP-conjugated anti-rabbit IgG secondary antibody. A specific band was detected for LC3B at approximately 15 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. GAPDH is shown as a loading control. This experiment was conducted under reducing conditions.

Considerations for LC3 Turnover Assays	ICC/IHC	WB
1. In cells or tissues with high basal autophagy flux it may be difficult to detect additional autophagy induction.	$\checkmark$	
2. To avoid signal saturation, treatment with inhibitors should be limited to 1–2 hours.	$\checkmark$	$\checkmark$
3. Incubation periods with inhibitors and their concentrations should be closely monitored to prevent triggering cell death.	$\checkmark$	$\checkmark$
4. The use of fusion blockers (autophagosome-lysosome) may lead to the formation of larger autophagosomes and complicate analysis of autophagic activity.	$\checkmark$	

### **Alternate Targets to Study Autophagy**

p62/SQSTM1 Degradation Assay (WB, FC, ELISA, ICC/IF): Removal of cytosolic p62/SQSTM1 occurs primarily by autophagy. Therefore, the level of p62/SQSTM1 is inversely correlated to autophagic activity. Similar to LC3-II, blocking degradation of cytosolic components with Chloroquine, inhibits autophagic flux and leads to the accumulation of p62/SQSTM1. The levels of p62/SQSTM1 may be quantitated by flow cytometry, immunoblot and ELISA and serve as a biomarker for the analysis of autophagic flux.



Figure 8. p62/SQSTM1 is targeted to the autophagosome by interacting with LC3-II via its LIR domain. The UBD domain allows p62/SQSTM1 to bind ubiquitinated cytosolic components (e.g., protein aggregates), targeting them for degradation. Through the PB1 domain p62/SQSTM1 self-oligomerizes or dimerizes with NBR1.

### p62/SQSTM1- Structural Domains Relevant in Autophagy

Domains	Function
Johnamo	
PB1 (Phox and Bem1 Domain)	Self-oligomerization or heterodimerization with NBR1
UBD (Ubiquitin Binding Domain)	Interaction with ubiquitinated proteins
LIR (LC3 Interacting Region)	Human LIR motif: 335-DDDWTHLS-342



Figure 9. Cultured HeLa cells were treated with vehicle (H<sub>2</sub>O) or with 50  $\mu$ M Chloroquine for 24 hours as indicated. Cell lysates were prepared and separated on a 12% gel by SDS-PAGE. Protein was transferred to PVDF membrane and blocked in 5% non-fat milk. The membrane was then probed with 1  $\mu$ g/mL anti-p62/SQSTM1 [catalog# NBP1-48320] in 1% milk and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the upregulation of p62 (arrowhead) in response to Chloroquine treatment which indicates the blockage of autophagy.

### Considerations for p62/SQSTM1 Quantitation

For western blot analysis of p62/SQSTM1, care must be taken with the specific lysis and sample buffers used. p62/SQSTM1 oligomerizes upon inhibition of autophagy (e.g., lysosomotropic agents) and in the presence of protein aggregates leading to its accumulation in the Triton X-100 insoluble fraction. Therefore, a lysis buffer containing 1% SDS is more effective, allowing researchers to evaluate the entire p62/SQSTM1 cellular pool.

In comparison to LC3-II, turnover of p62/SQSTM1 occurs at a slower rate, therefore evaluation of degradation (e.g., after autophagy induction) should include time points beyond 24 hours. To evaluate autophagic flux via p62/SQSTM1 degradation, a combination of western blot and immunostaining in the presence and absence of autophagy inhibitors and inducers is recommended.



Figure 10: HeLa cells mock (left) and treated with 50 μM Chloroquine for 24 hours (right) were fixed in 4% paraformaldehyde at room temperature for 15 minutes. (Green): SQSTM1 protein stained by SQSTM1 antibody (1478) [catalog# NBP2-43663] diluted at 1:1000. (Red): Actin stained with Phalloidin diluted at 1:200. (Blue): Hoechst 33342 staining.

#### **Additional Recommended Targets to Monitor Autophagy**

Target	Method	Considerations
mTOR AMPK and	WR IP	Levels of ULK1 in some systems are too low to detect phosphorylated forms.
ATG1/ULK1*	Kinase Assay	TOR activity inversely correlates with autophagic activity, although TOR independent pathways also control autophagy.
ATG12, ATG5 and ATG16L1	ICC/IF	Conjugation of ATG12-ATG5 may reflect autophagic activity, but in some cells these proteins mainly exist in the conjugated form.
WIPI (endogenous WIPI1 or WIPI2)	ICC/IF	WIPI positive puncta may not be present in all cells.

\*ULK1 serves as a switch for autophagy regulation, mTOR and AMPK directly phosphorylate ULK1 inhibiting or activating its function, respectively.





Figure 11. **A.** Non-transfected (-) and transfected (+) 293T whole cell extracts (30 µg) were separated by 5% SDS-PAGE, and the membrane was blotted with mTOR antibody [6611] [catalog# NBP2-43658] diluted at 1:500. **B.** HeLa cells mock (left) and treated with 50µM Chloroquine for 24 hours (right) were fixed in 4% paraformaldehyde at room temperature for 15 minutes. (Green): ATG12 protein stained by ATG12 antibody [166] (catalog# NBP2-43781) diluted at 1:1000. (Red): F-actin stained with Phalloidin.

### Additional Methods to Monitor Autophagy

Assay	Method
Morphological identification and quantification of autophagosomes and autolysosomes.	TEM
GFP-LC3, monitors number of puncta as a measure of autophagic flux.	FM
Tandem mRFP/mCherry-GFP-LC3, monitors the change in fluorescence (yellow to red) as a measure of autophagic flux.	FM
GFP-LC3 Lysosomal delivery and proteolysis, monitors free GFP as a measure of autophagic flux.	WB

# **Simple Western for Autophagy Targets**

Simple Western is a new alternative to conventional western blotting. It provides an automated capillary-based platform for reproducible detection and quantitation of protein targets. Protein separation may be based on size or charge properties, and a wide range of molecular sizes (2-440 kDa) may be resolved in a multiplexed platform.



Figure 12. In the Simple Western System, separation of proteins and immunoprobing are performed within a capillary cartridge.

- Samples are first loaded onto a stacking matrix and proteins are separated according to size or charge as they move through a separation matrix.
- 2. Following protein immobilization, immunoprobing with primary and secondary antibodies is performed automatically.
- Detection is based on the use of a chemiluminescent reagent.
- 4. Simple western automatically provides quantitative information for detected proteins including molecular weight, signal intensity and background or noise measurements.
- 5. Sample separation is presented as a virtual image similar to a conventional blot.



Figure 13. **A.** p62/SQSTM1 Antibody [catalog# NBP1-48320] -Simple Western lane view shows a specific band for p62/SQSTM1 in 1.0 mg/mL of HeLa lysate. **B.** Simple Western lane view shows lysates of NIH-3T3 mouse embryonic fibroblast cell line treated with vehicle ( $H_2$ 0) (-) or treated (+) with 50 µM Chloroquine for 18 hours, loaded at 0.2 mg/mL. A specific band was detected for LC3B at approximately 17 kDa (as indicated) using 5 µg/mL of Rabbit Anti-Human LC3B Monoclonal Antibody (catalog# NBP2-59800). These experiments were conducted under reducing conditions and using the 12-230 kDa separation system.

### **Bio-techne: Select Autophagy Antibodies** Validated for Simple Western

Target	
LC3A	HIF1 α
LC3B	ATG5
p62/SQSTM1	ATG7
PINK1	Beclin1

To learn more go to: www.proteinsimple.com/simple\_western\_overview

## **Modulators of Autophagy**

Modulation of autophagy is attractive as this process is implicated in various disease states including cancer, neurodegeneration and cardiomyopathies. Small molecules able to inhibit or induce autophagic activity provide a mechanism to modulate and study autophagy at the single cell and organismal level. In contrast to genetic models, pharmacological agents allow temporal and dose control. Moreover, often the effects of autophagy modulating agents is reversible. For animal model systems, targeted delivery of autophagy modulators to specific organs and tissues may represent a significant advantage.

### **Small Molecule Modulators**

	Pharmacological Compound	Mode of Action
(0	3-Methyladenine	AMPK inhibitor
itor	(±)-Bay K 8644	L-type Ca <sup>2+</sup> channel activator
nhib	Spautin 1	USP10 and USP13 inhibitor
l (ge	LY 294002 <sup>*,a</sup>	
ophá	Wortmannin <sup>a</sup>	VP334 IIIIIbitoi
Aut	MRT 67307	
	MRT 68921	ULK IIIIIBIOI
	Simvastatin <sup>a</sup>	AMPK activator
	A 769662 °	AIVER ACTIVATOR
	Rapamycin <sup>a</sup>	
	Torins (1 and 2)	mTOD inhibitor
	Everolimus	
	PI 103	
	Dexamethasone	Anti-inflammatory glucocorticoid; may act via mTOR pathway
	L-690,330	Inositol monophosphatase inhibitor; independent of mTOR inhibition
ß	Dorsomorphin	AMPK inhibition-independent
ator	A23187, free acid <sup>a</sup>	
ctiv	Brefeldin A <sup>a</sup>	Courses EB atrace
gy A	Thapsigargin <sup>a</sup>	Causes ER Stress
opha	Tunicamycin <sup>a</sup>	
Auto	Amiodarone	Causes mitochondrial fragmentation and cell death
	GF 109203X	Protein kinase C inhibitor
	NF 449 <sup>a</sup>	Highly selective P2X1 antagonist; Gsa-selective antagonist
	Perifosine	PKB/AKT inhibitor
	Trichostatin A	Histone deacetylase inhibitor
	Nimodipine	$Ca^{2+}$ channel blocker (Ltype)
	Verapamil	
	3-Nitropropionic acid	Irreversible mitochondrial respiratory complex II inhibitor
	Rilmenidine	$\alpha 2$ agonist and I1 ligand; thought to enhance autophagy
	Valproic acid	Reduces inositol levels

<sup>a</sup> Commonly used modulators. \*VPS34 inhibitor more selective in comparison to 3-Methyladenine and Wortmannin.

Autophagy modulators available at Tocris: www.tocris.com/autophagy

### **Specific Induction of Autophagy: Tat Beclin Peptides**

Tat-Beclin peptides provide a very specific approach for the induction of autophagy, preventing the activation of other biologically significant pathways. Tat-Beclin peptides are designed based on the Beclin 1/Nef interacting sequence and coupled to the HIV-1 Tat protein transduction domain (PTD) sequence. The resulting peptide traverses the cell membrane and gains access to its key interacting partner, GAPR-1 (Golgi-associated plant pathogenesis-related protein 1), resulting in the induction of autophagy. The new Tat Beclin peptides (Tat-D11, Tat-L11) are shorter than the original peptide and induce autophagy more efficiently.

To learn more go to: www.novusbio.com/autophagy-inducing-peptides



Figure 14. GAPR-1/GLIPR2 is a negative regulator of autophagy and binds Beclin 1 to inhibit autophagy. In the presence of Tat-D11 peptides, Beclin 1 bound to GAPR-1 is released allowing Beclin 1 to mediate autophagosome formation and autophagy induction.



Figure 15. Tat-D11 and Tat-L11 are more potent autophagy inducers than Tat-Beclin 1. HeLa GFP-LC3B were treated with Tat-D11, Tat-L11, Tat-L11S or Tat-Beclin for 1.5 hours, and (A) the number of autophagosomes were assessed by fluorescent microscopy and (B) the number of GFP+/ LC3B+ spots were quantified. Cells treated with Tat-D11 had larger numbers of GFP+/ LC3B+ puncta.

# **Nuclear Control of Autophagy**

Many transcription factors are known to regulate the expression of key autophagy related genes. Transcriptional regulation has rapid outcomes on autophagic activity. Often, translocation of transcription factors between the cytoplasm and the nuclei determines their specific function as modulators of autophagy. Nevertheless, each regulatory axis seems to influence autophagy via unique mechanisms.

### **Transcriptional Mechanisms Regulating Autophagy**

Transcription Factor	Autophagy Outcome	Autophagy Rela	ated Genes Transcriptic	nally Regulated
E0X01		ATG5	BECN1	VSP34
ruxu1	+	ATG12	BNiP3	
(Catalog# NBF2-31370)		ATG14	LC3	
F0X03		ATG4	BNIP3	ULK2
(catalog# AF6165)	+/-	ATG12	LC3	VSP34
R&D Systems		BECN1	ULK1	
E2F1		ATG5	LC3	
(catalog# AF4825)	+	BNIP3	ULK1	
R&D Systems				
NF-кВ	17	BCL2	BNIP3	
(catalog# NBP1-77395)	+/-	BECN1	SQSTM1	
TFEB		ATG4	LC3	WIPI
(catalog# MAB9170)	+	ATG9	SQSTM1	
R&D Systems		BCL2	UVRAG	
ZKSCAN3		LC3		
(catalog# NBP2-47570,	-	ULK1		
NBP1-31566)		WIPI		

Autophagy outcome: + (Enhanced), - (Decreased).

### **Nuclear Control of Autophagy**



#### Figure 16.

Transcriptional regulation of autophagy. The core autophagy machinery comprising all steps of the pathway can be regulated by nuclear transcription factors.

### **Epigenetic Control of Autophagy**

The role of various epigenetic changes including chromatin and histone modifications on the modulation of autophagy has prompted intense scrutiny. Regulatory pathways involving DNA and histone modifying enzymes dynamically fine-tune the process of autophagy. Several significant modifying enzymes have been identified that induce or inhibit autophagic activity.

### Identified Epigenetic Changes Influencing Autophagy

Enzymatic Mechanism	Autophagy Related Genes Modulated	Associated Autophagic State
DNMT2	ATG5 and LC3 downregulated	Reduced autophagy
Hypermethylation		
ESA1/RPD3 axis	Ribosomal Protein upregulated/ downregulated	Reduced/Increased autophagy
Acetylation/Deacetylation of H4	LC3 expression regulation	
G9A	LC3, WIPI1 and DOR downregulated	Reduced autophagy
Methylation of H3K9		
hMOF/SIRT1 axis	Autophagy related genes induced/	Balance between cell death and survival
Acetylation/Deacetylation of H4K16	inhibited	
USP44 deubiquitination of H2B	Downregulated genes: regulation of NF-ĸB and biosynthetic process Upregulated genes: innate immunity and polyubiquitination	Increased autophagy

# Advanced Cell Diagnostics (ACD) RNAscope®

The RNAscope® assay is a proprietary RNA *(in situ)* hybridization (ISH) assay based on ACD's patented signal amplification and background suppression technology, which advances RNA biomarker analysis in tissues and cells. Unique to this technology, the RNAscope® assay delivers quantitative, sensitive, and specific molecular detection of RNA targets on a cell-by-cell basis with morphological context. An assay can be designed for any gene in any species and delivered in 2 weeks.

#### Signal Amplification is Achieved by a Cascade of Hybridization Events

- Step 1: ~ 20 Double Z target probes hybridize to the RNA target (targeting ~1kb region)
- **Step 2:** Pre-amplifiers hybridize to the 28-base binding site formed by each double Z probe. Hybridization of only one Z probe will inhibit binding of the pre-amplifier, thereby providing high specificity.
- Step 3: Amplifiers recognize multiple binding sites on each preamplifier.
- **Step 4:** Labeled probes, containing a fluorescent molecule or chromogenic enzyme, bind to the numerous binding sites on each amplifier. This signal amplification system increases assay sensitivity.



Catalog Number	Product Name	Species	Gene Alias
469441	RNAscope® Probe - Mm-Pnpla2	Mouse	Atgl
469711	RNAscope® Probe - Mm-Atg5	Mouse	Atg5
434111	RNAscope® Probe - Hs-BECN1	Human	ATG6
477991	RNAscope® Probe - Mm-Map1lc3b	Mouse	Atg8f
492821	RNAscope® Probe - Hs-MAP1LC3B	Human	ATG8f
445401	RNAscope® Probe - Hs-MAP1LC3A	Human	ATG8e
496561	RNAscope® Probe - Hs-WIPI1	Human	ATG18
434121	RNAscope® Probe - Hs-BECN1P1	Human	BECN2
415881	RNAscope® Probe - Hs-SQSTM1	Human	p62
444221	RNAscope® Probe - Mm-Sqstm1	Mouse	p62
477531	RNAscope® Probe - Hs-ANPEP	Human	p150
439731	RNAscope® Probe - Mm-Ulk1	Mouse	Ulk1

For more information go to: https://acdbio.com/science/applications

### **Select References**

- 1. Mizushima N. (2007). Autophagy: process and function. Genes Dev. 21:2861–2873. doi: 10.1101/gad.1599207
- Glick, D., Barth, S., & Macleod, K. F. (2010). Autophagy: cellular and molecular mechanisms. The Journal of Pathology. 221(1), 3–12. http://doi.org/10.1002/path.2697
- Yamada, E., & Singh, R. (2012). Mapping Autophagy on to Your Metabolic Radar. Diabetes. 61(2), 272–280. http://doi.org/10.2337/ db11-1199
- 4. van der Vaart, A., Mari, M., & Reggiori, F. (2008). A picky eater: exploring the mechanisms of selective autophagy in human pathologies. Traffic. 9(3), 281-9. doi: 10.1111/j.1600-0854.2007.00674.x
- Mancias, J. D., & Kimmelman, A. C. (2016). Mechanisms of selective autophagy in normal physiology and cancer. Journal of Molecular Biology, 428(9 Pt A), 1659–1680. http://doi.org/10.1016/j.jmb.2016.02.027
- Lippai M., & Lőw P. (2014). "The Role of the Selective Adaptor p62 and Ubiquitin-Like Proteins in Autophagy," BioMed Research International. 2014, Article ID 832704, 11 pages. doi:10.1155/2014/832704
- Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, et al. (2016). Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 12(1), 1–222. http://doi.org/10.1080/15548627.2015.1100356
- Mizushima, N., Yoshimorim, T., & Levine, B. (2010). Methods in Mammalian Autophagy Research. Cell. 140(3), 313–326. http://doi. org/10.1016/j.cell.2010.01.028
- 9. Vakifahmetoglu-Norberg, H., Xia, H., & Yuan, J. (2015). Pharmacologic agents targeting autophagy. The Journal of Clinical Investigation, 125(1), 5–13. http://doi.org/10.1172/JCI73937
- Galluzzi L., Bravo-San Pedro J.M., Levine B., Green D.R., Kroemer G. (2017). Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat Rev Drug Discov. 16(7), 487-511. http://dx.doi.org/10.1038/nrd.2017.22
- Shoji-Kawata, S., Sumpter, R., Leveno, M., et al. (2013). Identification of a candidate therapeutic autophagy-inducing peptide. Nature. 494(7436), 201–206. http://doi.org/10.1038/nature11866
- 12. Füllgrabe J., Ghislat G., Cho D.H., Rubinsztein D.C. (2016). 'Transcriptional regulation of mammalian autophagy at a glance'. Journal of Cell Science.129 (16), 3059-3066. doi: 10.1242/jcs.188920
- 13. Füllgrabe, J., Klionsky, D. J., & Joseph, B. (2014). The return of the nucleus: Transcriptional and epigenetic control of autophagy. Nature Reviews Molecular Cell Biology. 15(1), 65-74. doi: 10.1038/nrm3716
- 14. Lapierre, L. R., Kumsta, C., Sandri, M., Ballabio, A., & Hansen, M. (2015). Transcriptional and epigenetic regulation of autophagy in aging. Autophagy. 11(6), 867–880. http://doi.org/10.1080/15548627.2015.1034410
- 15. Füllgrabe, J., Lynch-Day, M. A., Heldring, N., et al. (2013). The histone H4 lysine 16 acetyltransferase hMOF regulates the outcome of autophagy. Nature. 500(7463), 468-471. doi: 10.1038/nature12313
- 16. Rohde, J. R., & Cardenas, M. E. (2003). The Tor Pathway Regulates Gene Expression by Linking Nutrient Sensing to Histone Acetylation. Molecular and Cellular Biology. 23(2), 629–635. http://doi.org/10.1128/MCB.23.2.629-635.2003
- 17. Khalil, H., Tazi, M., Caution, K., et al. (2016). Aging is associated with hypermethylation of autophagy genes in macrophages. Epigenetics, 11(5), 381–388. http://doi.org/10.1080/15592294.2016.1144007
- Artal-Martinez de Narvajas, A., Gomez, T. S., Zhang, J.-S., Mann, A. O., et al. (2013). Epigenetic Regulation of Autophagy by the Methyltransferase G9a. Molecular and Cellular Biology, 33(20), 3983–3993. http://doi.org/10.1128/MCB.00813-13

# **Acronyms and Abbreviations**

AMBRA1	Activating molecule BECN1 regulated autophagy protein 1
AMPK	AMP-activated protein kinase
ATG	Autophagy related proteins
BME	2-mercaptoethanol
BNIP3	BCL-2/adenovirus E1B 19 kDa interacting protein 3
CD40	Cluster of differentiation 40
Cue5	Coupling of ubiquitin conjugation to ER degradation
DNMT	DNA methyltransferase
DOR	Diabetes- and obesity-regulated
ELISA	Enzyme linked immunosorbent assay
ESA	Essential SAS2-related acetyltransferase
FAM134B	Family with sequence similarity 134 member B
FC	Flow cytometry
FIP200	FAK family-interacting protein of 200 kDa
FM	Fluorescent microscopy
FOXO	Forkhead box O
FUNDC1	FUN-domain containing protein
G9A	Euchromatic histone-lysine N-methyltransferase 2
GAPR-1	Golgi-associated plant pathogenesis-related protein 1
HSC-70	Heat shock cognate 70 protein
Hsp	Heat shock protein
ICC	Immunocytochemistry
IF	Immunofluorescence
IHC	Immunohistochemistry
ISH	in situ hybridization
КО	Knockout
LAMP-2A	Lysosomal associated membrane protein-2A
LC3	Microtubule-associated protein light chain 3
LIR	LC3 interacting region
МНС	Major histocompatibility complex
mTOR	Mammalian target of rapamycin
NBR1	neighbor of BRCA1 gene 1

NDP52	Nuclear dot protein 52 kDa
NIX	NIP3-like protein X
OPTN	Optineurin
PB1	Phox and Bem1 domain
PE	Phosphatidylethanolamine
PKB	Protein kinase B
PTD	Protein transduction domain
PtdIns3K	Class III phosphatidylinositol 3-kinase
RB1CC1	RB1-inducible coiled-coil 1
RPD3	Reduced Potassium Deficiency 3/Histone Deacetylase
RPN10	Regulatory particle non-ATPase
SIRT1	Silent Mating Type Information Regulation 2, S. Cerevisiae, Homolog 1
SQSTM1	Sequestosome 1
SMURF1	SMAD ubiquitylation regulatory factor
SNAP29	Synaptosome associated protein 29
STX17	Syntaxin 17
TAX1BP1	Human T-Cell Leukemia Virus Type I) Binding Protein 1
TCR	T-cell receptor
TEM	Transmission electron microscopy
TFEB	Transcription factor EB
TLR4	Toll-like receptor 4
TOLLIP	Toll-interacting protein
TRAIL	Tumor necrosis factor-related apoptosis- inducing ligand
TRIM5a	Tripartite motif
UBD	Ubiquitin binding domain
ULK1	unc-51-like kinase 1
USP	Ubiquitin Specific Peptidase
UVRAG	UV resistance-associated gene
VAMP8	Vesicle associated membrane protein 8
VPS	Vacuolar sorting protein
WB	Western Blot
WIPI	WD-repeat protein interacting with phosphoinositides
7KSCAN2	zinc finger with KRAB and SCAN domains 3

R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry. rndsystems.com

Novus Biologicals licenses, manufactures, and markets antibodies to over 20,000 unique targets to support a wide array of research areas. Novus is built on honesty, collaboration and strong relationships and continues to provide quality tools that accelerate research. Every product is backed by our 100% guarantee. novusbio.com

Tocris Bioscience is the leading supplier of high performance tools for life science research. The Tocris range of small molecules and peptides includes novel and exclusive receptor ligands, ion channel modulators, enzyme inhibitors, caged compounds, fluorescent probes, and screening libraries. tocris.com

ProteinSimple develops and commercializes proprietary systems and consumables for protein analysis that ultimately help reveal new insights into the true nature of proteins. Making protein analysis more quantifiable and affordable, their comprehensive portfolio of tools includes Simple Western<sup>™</sup> and Simple Plex<sup>™</sup> platforms that quantify protein expression and iCE and MFI<sup>®</sup> systems that probe the structure and purity of protein-based therapeutics. proteinsimple.com

# RDSYSTEMS









Globalinfo@bio-techne.combio-techne.com/find-us/distributorsTEL +1 612 379 2956North AmericaTEL 800 343 7475Europe | Middle East | AfricaTEL +44 (0)1235 529449Chinainfo.cn@bio-techne.comTEL +86 (21) 52380373

bio-techne.com 🗗 🏏 in 🛗 🖸

BR\_AutophagyHandbook\_091117\_25262